Cost-effectiveness analysis shows potential public health benefit of COVID-19 vaccination in high-risk adults, suggesting significant savings.
Vaccinating adults at high risk of severe COVID-19 with the LP.8.1-adapted Pfizer BioNTech COVID-19 Vaccine is projected to be a cost-saving measure from the societal perspective that could reduce the public health and economic burden of COVID-19.
No takes yet. Share an insight, caveat, or question.
Yehoshua et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: